The United States Patent and Trademark Office (USPTO) has issued two new patents to Palatin Technologies, Inc. Both patents support company's  programme developing synthetic mimetics of the neuropeptide hormone atrial natriuretic peptide.

These mimetics may be useful in treatment of acute asthma, other pulmonary diseases, heart failure, hypertension and other indications.

US Patent 8,580,747, entitled “Cyclic Natriuretic Peptide Constructs,” has composition of matter claims relating to Palatin’s PL-3994 natriuretic peptide receptor-A agonist for treatment of cardiovascular and pulmonary indications. PL-3994 has completed two early stage human clinical studies, a phase I trial in healthy volunteers and a phase IIA trial in volunteers with controlled hypertension.

US Patent 8,580,746, entitled “Amide Linkage Cyclic Natriuretic Peptide Constructs,” has composition of matter claims to a novel series of mimetics of atrial natriuretic peptide. These compounds have potential utility in a number of cardiovascular and pulmonary indications.

“We are pleased to have two new issued patents supporting our natriuretic peptide portfolio. Our mimetic peptides have a much longer half-life than endogenous atrial natriuretic peptide, giving them important drug-like properties,” stated Carl Spana, Ph.D., president and CEO of Palatin.

The issued patents have a twenty-year term that will not expire until March 2027.